The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Findings from arms 6 and 7 of the EPCORE NHL-2 trial: epcoritamab in newly diagnosed FL
Lorenzo Falchi, MD, Memorial Sloan Kettering Cancer Center, New York, NY, presents findings from arms 6 and 7 of the EPCORE NHL-2 clinical trial (NCT04663347) investigating epcoritamab in newly diagnosed high-burden follicular lymphoma (FL). Arm 6, investigating frontline epcoritamab with rituximab and lenalidomide (R2), showed a 95% overall response rate (ORR) and an 85% complete metabolic response (CMR) rate. Arm 7, studying epcoritamab maintenance following standard chemoimmunotherapy, also appears promising, though longer follow-up is needed to draw definitive conclusions. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory board: AstraZeneca, Genentech, Abbvie, Ipsen, ADC Therapeutics, Seagen; Consultancy: Genmab, Roche, Genentech, Abbvie, Evolveimmune; Honoraria: Genmab, Genentech, Abbvie; Travel Expenses: Genmab, Abbvie; Research Funding: Genmab, Roche, Genentech, Abbvie, Innate Pharma.
